title: [Private companies: an opportunity for hepatitis B virus (HBV) prevention and care in Ivory Coast in the wake of HIV/AIDS?].
abstract: In the 1990s, defenders of "aids exceptionnalism" have promised that the inequities caused by HIV/AIDS could provide leverage in the care of other health issues later. Fifteen years later, this argument can be rethought at the light of the current context of hepatitis B virus (HBV) in Ivory Coast. In fact, in this country, the challenges caused by HBVecho those of HIV/AIDS fifteen years ago: high prevalence (8-10%), ignorance of the disease, and high cost of care. To this end, this article compares the role of private companies in the fights against HIV/AIDS in the 2000s and its role in the fight against HBV today. Although some private firms played a critical role in the promotion of universal access to ART, today, they are one of the few places where HBV screening, vaccination and treatment are offered in the country. HIV/AIDS opened the door for private companies to address other diseases through their health care systems. However, many challenges still need to be met: the absence of qualitative ongoing training for health professionals, illness representations and the costs of treatments, which are all related to the lack of international and national collective action. In Ivory Coast, at the early stage of the HIV/AIDS epidemic, national authorities took up the leadership in the fight against AIDS in West Africa, by developing extraverted strategies (Xth ICASA's organization, Unaids initiative hosting). The exceptional international mobilization and the creation of innovative funding mechanisms [International Therapeutic Solidarity Fund (ITSF), Global Fund (GM), and President's Emergency Plan for AIDS Relief (PEPFAR)] have facilitated easy access to ARV. Although 380 million people are infected by chronic HBV in the world, even so, international and national collective actions are fledgling and remained weak. Moreover, private firms have represented leverage for testing, treatment, and the provision of universal access to medication in the context of the HIV/AIDS epidemic in Ivory Coast, as relayed by other public and private actors. In the HBV context, private companies can only be a vector for the development of a two tier healthcare system. Therefore, the lack of a strong international commitment prevents public and private local initiatives to generalize HBV prevention and treatment.
authors.affiliation: Centre population et développement (Ceped) UMR 196, Université Paris Descartes Sorbonne Paris Cité/Ined/IRD, Paris, France. anne.bekelynck@ceped.org.
authors.forename: A
authors.initials: A
authors.lastname: Bekelynck
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D007560:Cote d'Ivoire / Q000453:epidemiology; D003695:Delivery of Health Care / Q000191:economics / Q000458:organization & administration; D015658:HIV Infections / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D015497:HIV-1; D006269:Health Facilities, Proprietary / Q000458:organization & administration / Q000600:supply & distribution; D006509:Hepatitis B / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D006515:Hepatitis B virus; D006801:Humans; D007391:International Cooperation; D007857:Leadership; D017149:Private Sector / Q000191:economics / Q000458:organization & administration; D024382:Professional Role; D055818:Public-Private Sector Partnerships
keywords: Aids; Collective action; HIV; Hepatitis B virus (HBV); Ivory Coast; Private sector; Sub-Saharan Africa